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Introduction
Human granulocytic ehrlichiosis (HGE) is a newly recog-
nized tickborne infection of humans (1–3). HGE is a
febrile illness characterized by reductions in blood leuko-
cyte and platelet counts and the presence of colonies of
infecting organisms (morulae) proliferating within cyto-
plasmic vacuoles of circulating neutrophils. No other
organism is known to replicate within human granulo-
cytes. Our laboratory recently isolated and propagated
the causative agent of this disease using the human
promyelocytic leukemia cell line HL60 (4). In addition, we
found that the agent can grow in primary bone marrow
granulocytic and monocytic precursors, blood neu-
trophils, and nonactivated monocytes (5).
The clinical and in vitro tropism of this obligate intra-
cellular parasite for myelomonocytic cells suggested that
specific cell-surface molecules are required for adhesion,
cell signaling, and entry into a permissive intracellular
compartment. Of interest, sialyl Lewis x ([NeuAcα(2−
3)GalΒ1−4(Fucα1–3)GlcNAc, or CD15s]), which serves as
a ligand to initially tether leukocytes to endothelial cell E-
selectin (6, 7), is richly expressed on both HL60 cells and
on those bone marrow and blood cells permissive for the
HGE agent (8–11), where it modifies a variety of lipid and
protein molecules. We hypothesized that cell-surface sia-
lylated Lewis x might be important for infection by HGE.
Methods
HGE infection, cultivation, and antibody blocking studies. A cell-free
bacterial inoculum of HGE was prepared from fully infected
HL60 cells, propagated as described (4). The infected cells, at a
density of 106 per ml, were passed through a 25-gauge needle
three times, and cellular debris were removed by centrifugation
at 700 g for 5 min. The supernatant was centrifuged at 1,236 g
for 5 min, and the resultant bacterial pellet was resuspended in
10 µl supernatant per ml of the original culture. Counting in a
Petroff-Hausser chamber revealed ∼ 107 organisms per 10 µl.
Infections were carried out by coincubating 10 µl of this cell-free
HGE preparation with 106 cells for a multiplicity of infection of
∼ 10 organisms per cell used in all experiments. For studies to
determine whether bacterial binding requires calcium, both
HL60 cells and the bacterial inoculum were separately incubat-
ed in HBSS with or without calcium for 20–70 min before coin-
cubation, as described later here. For blocking studies, 10 µg (or
the quantity specified) of the monoclonal antibody (MAB) test-
ed (or control diluent or murine IgM alone) was added to 1 ml
of 106 HL60 cells (or bone marrow progenitors, peripheral blood
monocytes, or granulocytes, prepared as described; ref. 5) in
medium and incubated at room temperature for 1 h. Blocking
studies were performed six times with similar results. As noted,
antibody blocking studies were also performed at 4°C or 37°C.
Cells were centrifuged at 200 g for 5 min, 900 µl of supernatant
saved, the cells resuspended in the 100 µl of medium remaining,
and 10 µl of the HGE bacteria added and then coincubated for
15 min at room temperature. The cells were then washed and
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pelleted three times in growth medium and resuspended in the
retained 900 µl of medium containing the MAB. In experiments
to determine the effects of anti-CD15s on bacteria that had
already entered cells, 50 µg/ml of gentamicin was added to the
cultures for a period of 1 h, at time points from 4 to 18 h after
incubation with bacteria. This procedure killed any remaining
infectious extracellular organisms (data not shown), thus
enabling assessment of the effects of antibody on intracellular
organisms alone. Cells were incubated as described (4, 5) and
assessed for infection (see later here) daily.
Monoclonal antibodies. The anti-CD15s antibody CSLEX1 (12)
was obtained from Becton Dickinson Immunocytometry Sys-
tems (San Jose, California, USA); KM93 (13) from Kamiya Bio-
medical (Tukwila, Washington, USA); and 2H5 (14) and 2F3
(15) from PharMingen (San Diego, California, USA). VIM-2
(16) was obtained from BioSource International (Camarillo,
California, USA). Control antibodies were kindly provided by
Keith Skubitz (Division of Oncology, University of Minnesota).
Immunofluorescent and electron microscopy. For immunofluores-
cent detection of CD15s and/or HGE antigens, respectively,
cytospin preparations of 105 cells were fixed with methanol/ace-
tone (1:1) and probed at room temperature for 1 h with CSLEX1
(0.25 µg/ml) or anti-HGE serum (diluted 1:200 from a culture-
positive patient with an immunofluorescent antibody [IFA] titer
of 1:5,120), each diluted in Tris-buffered saline with 3% BSA.
Goat anti–mouse IgM was used as the second antibody to detect
CD15s, and goat anti–human IgG was used to detect HGE anti-
gens (both from Organon Teknika Corp., West Chester, Penn-
sylvania, USA). For electron microscopy, cells were prepared by
pelleting at 94 g followed by resuspension in a phosphate-
buffered fixative of 4% paraformaldehyde, 2.5% glutaraldehyde,
and 0.1 M sucrose (pH 7.0). The cells were embedded in agarose,
postfixed with reduced osmium, and subjected to a mordanting
process using tannic acid before embedding, sectioning, and
staining with KMnO4 as described (17).
Neuraminidase treatment and evaluation of bacterial adhesion and
infection. Neuraminidase Type X (Sigma Chemical Co., St. Louis,
Missouri, USA) was dissolved in 0.5 ml of 0.15 M NaCl, 5 mM
CaCl2 (pH 6.0) at the concentrations specified. HL60 cells (106)
were incubated in this buffer (with or without enzyme) at 37°C
for 2 h. Neuraminidase-treated and -untreated control cells
were then washed in medium, pelleted, resuspended in 0.1 ml
of medium, and coincubated with 10 µl of cell-free HGE pre-
pared as described. For studying possible neuraminidase effects
on organisms, 107 identically neuraminidase-treated or -
untreated bacteria were coincubated with 106 HL60 cells. After
15 min at room temperature, cells were washed two times with
5 ml of medium to remove unbound bacteria. Cytospin slides
were prepared for indirect immunofluorescence microscopy to
evaluate bacterial adhesion and, at later time points, stained
with Giemsa to evaluate the development of infection. Bacter-
ial binding was quantitated by an observer blinded as to exper-
imental group, counting rhodamine-labeled HGE organisms
adherent to the surface of each of at least 100 cells per experi-
mental group. Similarly, infection (and blocking) was quanti-
tated by determining, in each experimental group, the percent-
age of 100 cells showing visible morula(e) at the indicated time
points. The statistical difference in adhesion and/or infection
was compared among experimental groups using two-tailed t
tests and χ2 analysis, respectively, utilizing Microsoft Excel soft-
ware (Microsoft Corp., Redmond, Washington, USA).
Selection and characterization of a cloned HGE-resistant HL60 sub-
line. HL60 cells were infected with the human isolate HGE-1 as
described (4). After infection, rare surviving cells were removed
and grown in the absence of the organism. The cell population
was then cloned twice by limiting dilution in 96-well plates,
and the cloned uninfected subline (HL60-A2) was again chal-
lenged with HGE and found to be resistant to infection. FACS
(Becton Dickinson Immunocytometry Systems) analysis for
relevant cell-surface antigens was performed using standard
methods and antibodies (18).
Fucosyltransferase assays. Cell extracts containing 1% Triton X-
100 were prepared from HL60, HL60-A2, and HL60-A2C cells
as described (19). Fucosyltransferase assays were performed in
a volume of 20 µl and contained 25 mM sodium cacodylate (pH
6.2), 5mM ATP, 10 mM L-fucose, 20 mM MnCl2, 3 µM GDP-
[14C]fucose, and 10 µg of cell-extract protein. The acceptor sub-
strate (N-acetyllactosamine, Galβ1 → 4GlcN Ac) was added to
a final concentration of 20 mM. Control assays with no added
acceptor were performed using the same conditions. Reactions
were incubated at 37°C for 1 h.
Terminated assays were centrifuged and the supernatants
were collected. An aliquot of each supernatant was subjected to
scintillation counting. Another aliquot was applied to a col-
umn containing Dowex 1X2-400 in the formate form. To quan-
titate incorporation of radioactive fucose into product, the
flow-through fraction and 2 ml of a subsequent water elution
were collected and counted. Amine-adsorption HPLC was used
to confirm the structure of the product formed as described
previously (19). For fucosyltransferase assays using α-(2,3)sia-
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Table 1
α-(1,3)fucosyltransferase activity in cellular extracts
Cell line Acceptor Mean enzyme activity
(pmol/mg/h ± SEM)
HL60 LacNac 1085 ± 93
Sialyl-LacNac 364 ± 25
HL60-A2 LacNac 3334 ± 176
Sialyl-LacNac 21 ± 8A
HL60-A2C LacNac 787 ± 60
Sialyl-LacNac 639 ± 71
AP < 0.05 vs. HL60 and HL60-A2C.
Figure 1
Anti-CD15s antibody blocks infection of HL60 cells by the HGE
agent. HL60 cells 3 days after incubation with the HGE agent in the
absence (a) or presence (b) of MAB against CD15s (CSLEX1; 10
µg/ml). a shows typical intracellular organisms (arrows) that are
absent in the antibody-treated cells (b). HGE, human granulocytic
ehrlichiosis; MAB, monoclonal antibody.
lyl-N-acetyllactosamine (NeuNAcα2 → 3Galβ1 → 4GlcN Ac;
Oxford GlycoSystems Inc., Jamaica, New York, USA) as the sub-
strate, terminated assays were centrifuged and the supernatants
were collected. A 200-µl aliquot of this material was subjected
to scintillation counting to determine the total amount of
radioactivity in the diluted assay. A second 200-µl aliquot was
applied to a Dowex 1-X8 (PO42–) column. The flow-through
fraction and three separate 1-ml water elutions were collected
and pooled, and an aliquot of this material was counted as a
measure of product formation (19).
Reconstitution of Fuc-TVII and CD15s expression to the CD15s-
deficient HL60-A2 cells. The plasmids pcDNA3-FUT7 (Fuc-TVII
coding region cloned downstream of the human cytomegalo-
virus (CMV) immediate early promoter in the EcoRI site of
pcDNA3 [Invitrogen Corp., Carlsbad, California, USA]) and
pcDNA3-CAT (chloramphenicol acetyl transferase [CAT] cod-
ing region cloned into the HindIII site), were linearized with
PvuI and cotransfected into HL60-A2 cells as described (20).
Transfected cells were maintained in fresh medium containing
200 µg/ml of G418 (Geneticin; GIBCO BRL, Grand Island,
New York, USA). After 3 weeks in G418, viable cells were
cloned by limiting dilution in 96-well plates. Positive cells were
selected if they expressed both CD15s (assayed by FACS) and
CAT (assayed enzymatically as described in ref. 21). A CD15s-
and CAT-expressing clone, HL60-A2C, was maintained in
medium without antibiotics for 1 week before challenge with
the HGE agent. Binding and infection assays were performed
as described for HL60-A2 cells.
Results
We first determined whether MABs directed against
CD15s would affect HGE infection of HL60 cells. After
treatment with 10 µg/ml of any of four different anti-
CD15s MABs (CSLEX1, KM93, 2H5, and 2F3), only
0%–1% of HL60 cells contained morulae 3–5 days after
inoculation vs. 30%–95% of cells (range among six experi-
ments) infected in the absence of anti-CD15s or with con-
trol MABs of the same (IgM) isotype (Fig. 1, a and b; P <
0.001, controls vs. anti-CD15s). Concentrations of
CSLEX1 or KM93 as low as 2.5–5 µg/ml, respectively,
completely prevented infection of HL60 cells (Fig. 2). The
VIM-2 MAB, directed against the closely related sialylated
CDw65 carbohydrate moiety, had irregular blocking activ-
ity noted only at the highest concentration tested (40
µg/ml), with a maximal reduction in infection to 60% of
the level seen in untreated controls, suggesting either non-
specific effects or biologic cross-reactivity of high concen-
trations of VIM-2 against CD15s (22). Anti-CD15s anti-
body was also tested for its ability to block infection of
those nontransformed cells likely to be natural targets of
the HGE agent: human marrow progenitors and periph-
eral blood monocytes and granulocytes (5). As observed in
HL60 cells, 10 µg/ml of MAB CSLEX1 prevented infection
of all of these cell types (P < 0.001 vs. untreated controls).
In contrast to the protective effects of anti-CD15s,
MABs directed against nonsialylated CD15 (SSEA-1,
AHN 1, and AHN 1.1), against leukocyte activation
markers CD66 (CD66-1 and 14) and CD67 (AHN-16),
and against the CD18 β-integrin subunit (60.3) had no
effect on infection. The inhibition of HGE infection by
anti-CD15s occurred whether infection was carried out
using infected HL60 cells or cell-free bacteria as the
inoculum. Preincubation of the bacterial inoculum
(rather than the target cells) with CSLEX1 (10 µg/ml for
1 hour at 37°C) did not prevent infection, nor did
CSLEX1 bind to isolated bacteria.
Functional binding by CD15s to its normal receptors,
the selectins, depends on the presence of its terminal sial-
ic acid and is eliminated by treatment with neu-
raminidase (23). We therefore tested whether neu-
raminidase treatment of HL60 cells would affect the
HGE agent’s ability to bind to and infect them.
Although more than 95% of control untreated cells
became infected, pretreatment with 0.15–1.5 U/ml of
neuraminidase, but not lower concentrations, com-
pletely prevented infection (P < 0.001). In addition, neu-
raminidase treatment eliminated specific HGE binding
to the HL60 cell surface (Fig. 3; 0.2 ± 0.4 bound bacteria
per cell after neuraminidase treatment vs. 2.5 ± 2.3 bac-
teria bound per untreated cell; P < 0.001). Conversely,
neuraminidase treatment of purified HGE did not result
in any loss of either bacterial binding or infectivity.
Given that the binding of lectins to cell-surface carbo-
hydrates such as CD15s is a calcium-dependent process,
we sought to determine whether HGE binding is calci-
um-dependent. In these studies, organisms and cells
were separately preincubated for 20 or 70 minutes in
Hanks’ balanced salt solution (HBSS), either with or
without calcium, before infection. Binding to HL60 cells
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Table 2
FACS analysis of relevant cell-surface antigens on cell lines studied
Cell line Antigen Mean fluorescence intensityA
HL60 Lewis x 610
Sialyl Lewis x 2895
VIM-2 105
HL60-A2 Lewis x 1270
Sialyl Lewis x 13B
VIM-2 301
HL60-A2C Lewis x 1189
Sialyl Lewis x 3110
VIM-2 88
ANegative control antibodies (mouse IgG1/IgG2) mean fluorescence index <10.
BP < 0.05 HL60-A2 vs. HL60 or HL60A2C.
Figure 2
Dose–response curve of inhibition of HGE infection of HL60 cells by treat-
ment of cells with anti-CD15s antibodies CSLEX1 (squares) and KM93 (dia-
monds), and with anti-CDw65 (VIM-2, x marks). Percent of inhibition given
is the reduction in the percentage of cells infected 72 h after inoculation
with HGE compared with control cells coincubated with control IgM.
was not calcium-dependent (e.g., mean 3.4 ± 2.9 vs. 3.64
± 2.8 bacteria bound per cell after 70 minutes without or
with calcium, respectively; P = 0.5).
To determine whether anti-CD15s antibodies, like neu-
raminidase treatment, block bacterial binding, HL60
cells were pretreated with CSLEX1 or the other anti-
CD15s MABs (10 µg/ml) for 1 hour at 4°C–37°C, and
then bacteria were added for 15 minutes at 4°C (to
examine adhesion) or 37°C (to allow entry), followed by
observation immediately, and 2 and 4 hours later, using
indirect immunofluorescence and electron microscopy.
No difference was noted in bacterial adhesion between
MAB-treated (whether at 4°C, 20°C, or 37°C) and 
-untreated cells. However, by electron microscopy, fewer
CSLEX1-treated cells (1%–2%) had intracellular organ-
isms noted at 2–4 hours after infection compared with
untreated cells (6%–20%; P < 0.05). In addition, by four
hours after infection, approximately half of those bacte-
ria seen within anti-CD15s–treated cells, but none of
those within control untreated cells, were noted to be
undergoing degeneration. By 24 hours, any organisms
that had entered the MAB-treated cells appeared to have
failed to move further into the cell’s interior and did not
multiply or develop beyond the ingestion stage.
Given these findings, we sought to determine whether
late treatment of cells with anti-CD15s, after bacterial
entry, could affect the fate of intracellular organisms. For
these experiments, cells were infected with HGE as
described, and gentamicin added for a period of 1 hour,
at either 4 or 18 hours after infection, to kill any organ-
isms that had not already entered the cell. CSLEX1 was
then added. When examined 72 hours after infection,
48%–57% of cells that had been treated with CSLEX1 were
infected vs. 77%–80% of control untreated cells (for each
of two experiments, P < 0.05). In addition, the vacuoles in
CSLEX1-treated cells contained fewer organisms, and
those organisms present often appeared to be damaged
and degenerating. Identical results were obtained when
MAB 2H5 was used as the postentry treatment.
An HGE-resistant HL60 cell line, HL60-A2, was cloned
from cells surviving previous infection. These cells have
no HGE present by IFA and are noninfectious when
added to other HL60 cells. By both FACS analysis and
IFA, HL60-A2 expresses CD15s on only <1% of cells but
expresses other sialylated surface molecules (e.g., CDw65)
normally. There is no evidence that HL60-A2 cells are
activated based on comparison with parental HL60 cells
of surface expression of CR3 (CD11b/CD18) and LFA-1
(CD11a/CD18) or based on superoxide production and
granule markers in response to the agonists FMLP and
PMA (24). Biochemical analysis revealed that HL60-A2
cells have a defect in the expression of enzymatic activity
consistent with the α-(1,3)fucosyltransferase enzyme Fuc-
TVII, responsible for the terminal fucosylation of CD15s
(25). This is indicated by their greatly reduced ability to
terminally fucosylate sialyl-LacNac compared with
parental HL60 cells, in contrast to their normal fucosyla-
tion of nonsialylated LacNac (Table 1). In addition, we
have recently shown that there is a marked reduction in
the level of transcription of the Fuc-TVII gene in HL60A-
2 cells, which also fail to adhere normally to cytokine-
stimulated endothelial cells. Inoculation of this cloned
subline with HGE ultimately resulted in infection of <1%
of the cells (vs. 99% of parental HL60 cells; P < 0.001).
Dual immunofluorescence with anti-HGE serum and
anti-CD15s (CSLEX1) revealed that, unlike the normal
CD15s-expressing parental HL60 cells that uniformly
bind bacteria (Fig. 4a; mean 3.8 ± 2.4 bacteria per cell) and
become infected (Fig. 4b), the HL60-A2 cells only bound
a mean of 0.03 ± 0.2 bacteria per cell (Fig. 4c; P < 0.001)
and subsequently infected (Fig. 4d) only the rare CD15s-
expressing cells present in the HL60-A2 line.
We next determined whether reconstitution of CD15s
expression to HL60-A2 cells would result in restoration of
HGE binding and cellular susceptibility to infection.
HL60-A2 cells were transfected with an expression plas-
mid containing the FucT-VII and CAT coding regions and
were selected for neomycin resistance. Cloned transfec-
tants were assayed for CD15s expression, α-(1,3)fucosyl-
transferase and CAT activity. A CD15s-positive cell line,
HL60-A2C, derived from these selections, and the original
CD15s-negative HL60-A2 cells were then challenged with
HGE. Unlike HL60-A2 cells, the FucT-VII–transfected
HL60-A2C cells (but not transfection controls) all exhib-
ited high-level CD15s expression, bound the HGE bac-
terium avidly (Fig. 4e; mean 3.5 ± 3.4 bacteria per cell; P <
0.001 vs. HL60-A2 cells), and became infected (Fig. 4f).
Results of FACS analyses (Table 2) confirm the marked
deficiency of CD15s expression in HL60-A2 cells (despite
normal CD15 and VIM-2 expression) and the reconstitu-
tion of CD15s expression in HL60-A2C cells.
Cultured CD34+, HLA-DR+ normal human bone mar-
row cells, which we have shown are susceptible to infection
with HGE (5), contain an evolving population of cells with
variable CD15s expression. To determine whether bacter-
ial adhesion to these cells correlates with their CD15s
expression, we performed dual immunofluorescence stud-
ies of maximally susceptible 4-day-old bone marrow pro-
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Figure 3
Neuraminidase pretreatment inhibits HGE adhesion to HL60
cells. Specific cell-surface binding of rhodamine-labeled HGE
organisms (arrows) is present in untreated HL60 cells (a) but
absent in cells pretreated with neuraminidase (b).
genitor cultures inoculated with HGE. Individual cells
were first characterized by fluorescein CSLEX1 labeling
into high, intermediate, or low–null expressors of CD15s,
and the bacteria bound to each cell then enumerated
under rhodamine visualization. The binding of HGE to
the cell surface directly correlated with CD15s expression.
High expressors of CD15s bound a mean of 3.66 bacteria
per cell vs. 1.70 for intermediate and 0.63 for low–null
expressors (P < 0.05 for all comparisons). Finally, we simi-
larly determined whether the binding of HGE to HL60
cells also correlates with the expression of CD15s by indi-
vidual cells, which is heterogeneous in low-passage HL60
cultures. Indeed, we found that those wild-type HL60 cells
that did not visibly express CD15s seldom bind HGE
(mean 0.0 ± 0.0 bound bacteria per cell), whereas normal
CD15s-expressing cells avidly bound the bacterium (mean
5.5 ± 3.6 bacteria per cell; P < 0.0001 vs. nonexpressors).
Discussion
The data presented demonstrate that CD15s and/or a
very closely related sialylated and Fuc-TVII α-(1,3) fuco-
sylated molecule plays a critical role in the infection of
human hematopoietic cells by the HGE agent. Infection
of (but not binding to) susceptible cell types is blocked
by MABs against CD15s, and neuraminidase treatment
of cells abolishes bacterial binding and infection. HGE
binding to both HL60 cells and bone marrow progeni-
tors correlates directly with their surface CD15s expres-
sion. Finally, an HGE-resistant subline of HL60 cells,
which fails to bind HGE or become infected, is deficient
in the transcription and enzymatic activity of the Fuc-
TVII fucosyltransferase responsible for CD15s synthesis.
Genetic reconstitution of CD15s expression restores
these cells’ abilities to bind HGE and become infected.
All of these findings support an important role of
CD15s and/or a closely related molecule in HGE infec-
tion, possibly as a receptor component.
Although cell-surface CD15s was required for adhesion
of HGE to HL60 cells, it is notable that MABs against
CD15s, while preventing infection, did not prevent HGE
binding or entry. Thus, anti-CD15s MABs may not be
directed against the CD15s HGE-binding domain. The
CD15s carbohydrate itself is present on >107 molecules per
cell. Its underlying carbohydrate scaffolding varies in
length and branching, and CD15s modifies many differ-
ent proteins and sphingolipids (26, 27). Significant differ-
ences in biologic function can occur based on variations in
this scaffolding, and anti-CD15s MABs may not be capa-
ble of fully blocking binding to all of these moieties.
Alternatively, or in addition, the binding of HGE
and/or other ligands to specific CD15s-modified surface
proteins could lead to specific cell-signaling events (28,
29) and to endocytosis into an intracellular compartment
supportive of the agent’s growth. Therefore, anti-CD15s
antibodies could prevent HGE infection without altering
binding by affecting receptor conformation and/or by
triggering a change in the nature of cell entry, activation,
and/or endosomal trafficking or biochemistry. That anti-
CD15s MABs may act in such an indirect manner is sug-
gested by the significant attenuation of infection noted
even when antibody is added after bacterial entry. Final-
ly, the very close correlation of CD15s expression with
HGE binding and infection, but the failure of antibodies
to block binding, could be explained by the possibility
that a very closely related sialylated, as well as α-(1,3)
fucosylated, molecule, whose expression is also controlled
by Fuc-TVII, may be a key receptor component. The exis-
tence of such CD15s-coexpressed molecules has been
postulated as an explanation for otherwise unexplained
discrepancies noted in some instances between cellular
CD15s expression and binding to selectin ligands (30).
This is the first pathogen shown to involve CD15s in cel-
lular infection. CD15s, although present on many trans-
formed cells, is expressed primarily on blood and bone
marrow leukocytes, the cellular targets of HGE both in
vitro and in vivo. Our findings may explain, at least in part,
the organism’s unique cellular tropism. The agent’s inter-
actions with cell-surface CD15s may also affect disease
pathogenesis in less direct ways than by simply targeting
infection to permissive cells. These interactions could alter
subsequent leukocyte binding to the selectin ligands for
CD15s expressed on platelets, endothelium, and other
leukocytes. Such interactions may be important in the
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Figure 4
CD15s expression correlates with HGE adhesion to, and infection of,
HL60 cells. Photomicrographs of HGE antigens (rhodamine-labeled) and
CD15s expression (fluorescein-labeled) illustrating HGE binding to (time
0) and infection of (48 h): HL60 parent cells (a and b); the HGE-resist-
ant, CD15s-deficient cell line, HL60-A2 (c and d; fields selected to show
rare CD15s-expressing cells); and the CD15s-expressing Fuc-TVII trans-
fectant derivative, HL60-A2C (e and f). Typical bacterial adhesion and
intracellular colonies (arrows) are only observed in CD15s-expressing cells.
trafficking of this intracellular organism through the
bone marrow and the periphery and could evoke cell adhe-
sion–dependent disease manifestations (31–35). Struc-
turally similar carbohydrates have been previously impli-
cated in the pathogenesis of infection by other agents. For
example, nonsialylated Lewis x is expressed on the surface
of Schistosoma mansonii, and cell-surface expression of
Lewis b has been implicated in the binding of Helicobacter
pylori to gastric mucosal cells (36, 37).
The identification of specific CD15s-modified cell-
surface molecule(s) and/or associated or biochemical-
ly related receptor components that interact with the
HGE agent and, conversely, of the HGE molecule(s)
that interact with these sialylated and Fuc-TVII fuco-
sylated molecules, should define potential targets for
the prevention and treatment of infection. In addition,
further studies of the role of related cell-signaling
events in the cellular pathogenesis and outcome of
infection should provide insight into the unique abili-
ties of this agent to enter and then proliferate within
highly armed phagocytic cells.
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